Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD0780 Effect On LDL-C In ASCVD Patients Or At-Risk Individuals
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2025
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD0780 On Major Adverse CV Events In High-Risk ASCVD Patients
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2025
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients with HeFH
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2025
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AZ's Oral PCSK9 Inhibitor halves Bad Cholesterol in Phase 2
Details : AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Fortrea
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atherosclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Fortrea
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : YS2302018,Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
AstraZeneca Puts $2B on The Line for Preclinical Heart Disease Drug
Details : AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $100.0 million
October 07, 2024
Lead Product(s) : YS2302018,Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Laroprovstat
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Laroprovstat
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2024
Lead Product(s) : Laroprovstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable